A5052995463- Radiopharmaceutical Chemistry and Applications
- X-ray Diffraction in Crystallography
- Crystallization and Solubility Studies
- Radioactive element chemistry and processing
- Lanthanide and Transition Metal Complexes
- Organometallic Complex Synthesis and Catalysis
- Magnetism in coordination complexes
- Crystallography and molecular interactions
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Nuclear Materials and Properties
- Prostate Cancer Treatment and Research
- Peptidase Inhibition and Analysis
- Radioactive Decay and Measurement Techniques
- Synthesis and characterization of novel inorganic/organometallic compounds
- Radiation Therapy and Dosimetry
- Nuclear materials and radiation effects
- Inorganic Chemistry and Materials
- Metal complexes synthesis and properties
- Radioactive contamination and transfer
- Crystal structures of chemical compounds
- Chemical Synthesis and Characterization
- Radioactivity and Radon Measurements
- Chemical Thermodynamics and Molecular Structure
- Coordination Chemistry and Organometallics
Aristotle University of Thessaloniki
2012-2023
Joint Research Centre
2013-2022
European Commission
2002-2017
Karlsruhe University of Education
1993-2017
Hellenic Centre for Marine Research
2014-2015
Chimie de la Matière Condensée de Paris
2010-2011
Université Paris-Est Créteil
2010-2011
Centre National de la Recherche Scientifique
2010-2011
Johns Hopkins University
2009
University of Bucharest
2008
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. Although case series still ongoing, here report advance about two patients highly challenging clinical situations who showed complete response to <sup>225</sup>Ac-PSMA-617 therapy. <b>Methods:</b><sup>68</sup>Ga-PSMA-11 PET/CT validated presence of PSMA-positive tumor phenotype. A 100-kBq activity per kilogram body...
The aim of this study was to develop a treatment protocol for <sup>225</sup>Ac-PSMA-617 α-radiation therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with prostate-specific membrane antigen (PSMA)–positive tumor phenotype. <b>Methods:</b> A dosimetry estimate calculated on the basis time–activity curves derived from serially obtained <sup>177</sup>Lu-PSMA-617 scans extrapolated physical half-life <sup>225</sup>Ac, assuming instant decay unstable daughter...
Abstract Purpose Radiopeptide therapy using a somatostatin analogue labelled with beta emitter such as 90 Y/ 177 Lu-DOTATOC is new therapeutic option in neuroendocrine cancer. Alternative treatments for patients refractory disease are rare. Here we report the first-in-human experience 213 Bi-DOTATOC targeted alpha (TAT) pretreated emitters. Methods Seven progressive advanced liver metastases to treatment were treated an intraarterial infusion of Bi-DOTATOC, and one patient bone marrow...
This work describes a method for the separation and purification of Ac-225 from Th-229 source. The procedure is based on combination ion exchange extraction chromatographic methods in nitric acid media allows preparation carrier-free, clinical grade with an overall yield exceeding 95%. Quality control product performed using radiometric (α, γ spectrometry) mass spectrometric methods. can be loaded radionuclide generator Bi-213 preclinical studies targeted α therapy cancer infectious diseases.
Selective memory: Using actinides in designing molecular nanomagnets could provide better performance and higher anisotropy barriers, owing to the peculiar properties of 5f electron shell. Neptunocene is found display an open magnetic hysteresis cycle at low temperatures (see picture), interaction with hyperfine degrees freedom determines whether relaxation fast or slow a given field value.
alpha-Particles are suitable to treat cancer micrometastases because of their short range and very high linear energy transfer. alpha-Particle emitter (213)Bi-based radioimmunotherapy has shown efficacy in a variety metastatic animal models, such as breast, ovarian, prostate cancers. Its clinical implementation, however, is challenging due the limited supply (225)Ac, technical requirement prepare radioimmunoconjugate with half-life (T(1/2) = 45.6 min) on site, prohibitive cost. In this...
Glioblastoma multiforme (GBM), the most common malignant brain tumor, mainly manifests as a primary de novo and less frequently secondary glial neoplasm. GBM has been demonstrated to overexpress NK-1 receptor substance P can be used ligand for targeted therapy. Alpha emitters, e.g. 213Bi, that deposit their high energy within short range allow selective irradiation of tumor cells while sparing adjacent neuronal structures.Among 50 glioma patients different subtypes have date treated with...
Abstract Purpose The aim of this retrospective analysis is to estimate the most appropriate single cycle and cumulative doses 225 Ac-DOTATOC in patients treated for somatostatin-receptor-expressing cancers. Methods was administered thirty-nine with various somatostatin-receptor-positive tumors. Baseline follow-up 68 Ga-DOTATOC PET/CT, lab tests, renal scintigraphy were obtained. Patients received long-term either at local cancer center or close collaboration external oncologists. Acute...
Abstract Purpose: Malignant glial brain tumors consistently overexpress neurokinin type 1 receptors. In classic seed-based brachytherapy, one to several rigid 125I seeds are inserted, mainly for the treatment of small low-grade gliomas. The complex geometry rapidly proliferating high-grade gliomas requires a diffusible system targeting tumor-associated surface structures saturate tumor, including its margins. Experimental Design: We developed new vector by conjugating chelator...
Lanthanide-like: X-ray diffraction and density functional theory studies show that [An(H2O)9]3+ ions of the actinides U3+–Cf3+ in crystals their triflate salts have same structure electrostatic bonding as lanthanide counterparts La3+–Eu3+. Moreover, nine-coordinate geometry is essentially preserved solution for lighter elements (see picture). In recent years there has been considerable progress understanding chemistry low-valent synthesis techniques compounds. A significant number new...
Targeted α-therapy is an experimental approach to the management of cancer. Short range α-particle radiation from a radioisotope attached targeting monoclonal antibody kills targeted cancer cells. Survival results are analyzed previously reported Phase I study systemic for patients with stage IV metastatic melanoma or in-transit metastases. Following intravenous administration 46–925 MBq α-immunoconjugate, 213Bi-cDTPA-9.2.27, 38 were followed observe response and toxicity. Responses measured...
The ever-increasing use of wireless communication systems during the last few decades has raised concerns about potential health effects electromagnetic fields (EMFs) on humans. Safety limits and exposure assessment methods were developed are regularly updated to mitigate risks. Continuous radiofrequency EMF monitoring networks in situ measurement campaigns provide useful information environmental levels their variations over time different microenvironments. In this study, published data...
AbstractThis paper reports the development and application of intralesional targeted alpha therapy (TAT) for melanoma, being first part a program to establish new systemic therapy.RationaleLabelling benign targeting vector 9.2.27 with 213Bi forms alpha-immunoconjugate (AIC), which is highly cytotoxic melanoma cells.ObjectiveTo investigate safety efficacy AIC in patients metastatic skin melanoma.Findings16 were recruited. All positive monoclonal antibody 9.2.27. doses from 50 450 ?Ci injected...
Control of micrometastatic pancreatic cancer remains a major objective in treatment. The overexpression MUC1 mucin plays an important role metastasis. aim this study was to detect the expression human primary tumour tissues and three cell lines (CAPAN-1, CFPAC-1 PANC-1), target MUC1-positive cells vitro using 213Bi-C595 alpha-immunoconjugate (AIC). on performed by immunohistochemistry further confirmed confocal microscope flow cytometry analysis surface. Cytotoxicity tested MTS assay....
AbstractPurpose. The aim is to assess toxicity and response of systemic alpha therapy for metastatic melanoma.Experimental design. This an open-labelled Phase 1 dose escalation study establish the effective alpha-immunoconjugate 213Bi-cDTPA-9.2.27 mAb (AIC). Tools used investigate effects were physical examination; imaging tumours; pathology; GFR; CT changes in tumour marker. Responses assessed using RECIST criteria. Results Discussion. 22 patients with stage IV melanoma/ in-transit...